Streetbeat News

Assets

NVGS

Navigator Holdings Ltd. (NYSE: NVGS) has invested $2.5 million alongside Attis Clean Energy in Ten08 Energy to develop a clean ammonia production facility on the US Gulf Coast. The project aims to produce ultra-low carbon ammonia by late 2029/early 2030. Navigator has an option to invest up to $100 million at the Final Investment Decision stage.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:49 pm

QNRX

Quoin Pharmaceuticals reported having approximately $12.6 million in cash, cash equivalents, and marketable securities as of June 30, 2024. This funding is expected to support the company's operations into late 2025.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:33 pm

PHAT

Phathom Pharmaceuticals reported having $276.2 million in cash and cash equivalents as of June 30, 2024. The company believes this capital will be sufficient to fund its operations through the end of 2026.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:07 pm

CARM

Carisma Therapeutics announced that its cash and equivalents are expected to be sufficient to sustain its planned operations into the third quarter of 2025.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:05 pm

ICON

Icon Energy has announced the acquisition of a Kamsarmax dry bulk carrier for $17.57 million. The purchase will be financed through cash on hand and a new senior secured facility.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:00 pm

CVS

NLOP

Net Lease Office Properties (NLOP) has reported the sale of an office property leased to CVS Health for gross proceeds of $71.5 million.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:00 pm

CGEM

Cullinan Therapeutics reported having $664.9 million in cash, cash equivalents, investments, and interest receivable as of June 30, 2024. The company expects these resources to sustain operations until 2028 based on its current operating plan.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:00 pm

RAPP

Rapport Therapeutics ended the quarter with $336.1 million in cash, cash equivalents, and short-term investments, excluding restricted cash. This funding is expected to support operations through the end of 2026.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:58 am

PCT

PureCycle has reached an agreement to sell $22.5 million in Southern Ohio Port Authority Revenue Bonds, generating $18 million in cash proceeds. The company ended Q2 FY2024 with $10.9 million in unrestricted cash.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:58 am

IPSC

Century Therapeutics announced that it expects its cash runway to extend into 2026, providing financial stability for the next few years.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:53 am